Anaphylaxis is a life-threatening allergic reaction that is rapid in onset 1,2 . The frequency of anaphylaxis is estimated to be 50-2,000 episodes per 100,000 people 3 . Anaphylaxis can occur after exposure to certain allergens, such as foods, drugs, insect venoms, latex and immunotherapy injection 2 . Mast cells and basophils express FcεRI, the high-affinity receptor for immunoglobulin E (IgE), on the cell surface, and have a central role in IgE-associated anaphylaxis 4,5 . Crosslinking of FcεRI-bound IgE with multivalent antigen initiates the activation of mast cells and basophils by promoting aggregation of FcεRI. This process results in the degranulation of mast cells and basophils, with the concomitant secretion of chemical mediators, such as histamine, tryptase, carboxypeptidase A and proteoglycans, that are stored in the cytoplasmic granules of these cells; the de novo synthesis of proinflammatory lipid mediators, such as prostaglandins and leukotrienes, as well as platelet-activating factor, in the early phase (5-30 min after exposure to antigen); and the synthesis and secretion of cytokines and chemokines in the late phase (2-6 h after exposure to antigen) 6 . This anaphylactic reaction is called type I immediate hypersensitivity.
The signaling cascades mediated by FcεRI in mast cells have been extensively investigated 12 . FcεRI is a heterotetrameric receptor composed of an IgE-binding α-subunit, a four-transmembrane-spanning β-subunit and two disulfide-bonded γ-subunits (αβγ2). Aggregation of FcεRI by crosslinking of FcεRI-bound IgE induces activation of the Src family protein tyrosine kinase Lyn that is bound to the FcεRI β-subunit and activation of the nonreceptor protein tyrosine kinase Syk. The activated Syk then phosphorylates tyrosine residues in the immunoreceptor tyrosine-based activation motif of the β-and γ-subunits of FcεRI (ref. 13 ). This early step in the activation signal leads to the phosphorylation of adaptor proteins, including Lat, SLP76 and Vav, and to the activation of downstream signaling pathways 6 .
FcεRI-mediated mast cell activation is modulated by several cell-surface inhibitory receptors 14 , including FcγRIIB (CD32; A000556) 15 , PIR-B 16, 17 , gp49B1 (ref. 18 ), MAIR-I (also called CLM-8, LMIR1 or CD300a) [19] [20] [21] , MAFA 22, 23 and SIRP-α 24 . The cytoplasmic portion of these inhibitory receptors commonly contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs). When these inhibitory receptors are coligated with FcεRI, the tyrosine residue in the ITIM is phosphorylated and recruits the tyrosine phosphatases SHP-1 (A002156) and SHP-2 (A002157) and/or the inositol phosphatase SHIP (A002154), thereby blocking the early step in the activation signal mediated by FcεRI. The regulatory mechanisms of FcεRI-mediated mast cell activation have not been completely elucidated, and a molecular target that controls allergic responses for the prevention or treatment of anaphylaxis has not been identified. Here we identify a previously unknown inhibitory immunoglobulinlike receptor, allergy inhibitory receptor 1 (Allergin-1), that was 6 0 2 VOLUME 11 NUMBER 7 JULY 2010 nature immunology A r t i c l e s preferentially expressed on mast cells, and we explore its role in mast cell-mediated allergic responses in vivo and in vitro.
RESULTS

Identification of the gene encoding Allergin-1
To study the role of cell surface receptors in regulating the differentiation and activation of hematopoietic cells, we cloned several cDNA fragments encoding putative transmembrane proteins from a cDNA library derived from the human bone marrow stromal cell line HAS303 (ref. 25) by using the signal sequence-trap method 26 . We isolated full-length cDNAs from a random-primed cDNA library derived from the HAS303 cell line. We identified cDNA encoding Allergin-1L (Allergin-1 long form), which included a 19-amino acid leader sequence, a 208-amino acid extracellular region composed of two immunoglobulin-like domains, a 21-amino acid transmembrane domain and a 95-amino acid cytoplasmic domain (Fig. 1a,b) . We also identified two cDNAs encoding Allergin-1 isoforms that lacked the first or second immunoglobulin-like domain in the extracellular portion; we called these Allergin-1S1 (Allergin-1 short form 1) and Allergin-1S2 (Allergin-1 short form 2), respectively (Fig. 1b) . The extracellular portions of mouse Allergin-1 and human Allergin-1L and those of human Allergin-1S1 and Allergin-1S2 contained six and three potential N-linked glycosylation sites, respectively (Fig. 1a,b) .
Genomic DNA database analysis demonstrated that the human gene encoding Allergin-1 consisted of ten exons, but those encoding Allergin-1S1 and Allergin-1S2 lacked exons 4 and 3, respectively (Supplementary Fig. 1) . A database search identified mouse and rat homologs of Allergin-1 that contained a single immunoglobulinlike domain with amino acid identities of 50% and 52% with that of human Allergin-1S1 (Fig. 1a,b) . Although the rat Allergin-1 cDNA has been reported to be MCA- 32 (ref. 27) , the molecular and functional characteristics of Allergin-1 have not been reported. The gene encoding Allergin-1 is located on chromosome 17q23.3 in humans (ALLERGIN-1) and chromosome 11E1 in mice (Allergin-1), near genes of the Cd300 family that encode immunoglobulin-like receptors that mediate positive or negative signaling in myeloid cells 28, 29 (Fig. 1c) . Allergin-1 was also close to the gene encoding PECAM-1 (CD31), an ITIM-bearing immunoglobulin-like receptor expressed on myeloid cells and platelets. Genomic DNA database analysis demonstrated that like PECAM-1, but unlike CD300, Allergin-1 is encoded by a single gene in both human and mouse (data not shown).
Biochemical characteristics of Allergin-1
To study the biochemical characteristics of Allergin-1, we established transfectants of the RBL-2H3 rat basophil leukemia cell line and Ba/F3 pro-B cell line stably expressing mouse Allergin-1 tagged with Flag protein at the amino terminus ( Supplementary  Fig. 2 ). Immunoprecipitation of Allergin-1 protein from lysates of RBL-2H3 transfectants, followed by immunoblot analysis with antibody to Flag (anti-Flag), showed that mouse Allergin-1 had a molecular mass of ~60 kilodaltons (kDa) under both reducing and nonreducing conditions (Fig. 1d) , which suggested that mouse Allergin-1 is a monomeric protein. However, the molecular masses of human Allergin-1L, Allergin-1S1 and Allergin-1S2 seemed to be ~70 kDa, ~40 kDa and ~40 kDa, respectively, under reducing conditions (Fig. 1e) , although we also observed bands of greater molecular mass for human Allergin-1S1 and Allergin-1S2 as well as mouse Allergin-1 (Fig. 1d,e) . As both mouse and human Allergin-1 contained several potential N-linked glycosylation sites, these 'plural' bands might be dependent on different mobilities of the heavily glycosylated proteins. Indeed, treatment with N-glycosidase F substantially decreased the mass of mouse and human Allergin-1, consistent with that of the polypeptide we predicted from the Allergin-1 cDNA and the presence of potential N-linked glycosylation sites in the extracellular portion (Fig. 1d,e) .
Expression of Allergin-1
To investigate the cellular distribution of Allergin-1 expression, we generated monoclonal antibodies to mouse Allergin-1 (Fig. 2a) . (Fig. 2b) . However, mast cells from the peritoneal cavity had the highest expression of Allergin-1 (Fig. 2c) . Bone marrow-derived cultured mast cells (BMMCs) also expressed Allergin-1 (Fig. 2d) . In contrast, we did not detect Allergin-1 on basophils from the bone marrow (Fig. 2e) . These results suggest that Allergin-1 may be involved in immune responses mediated by myeloid cells. We also generated a monoclonal antibody (mAb) that specifically recognized human Allergin-1L and Allergin-1S1 but not Allergin-1S2 (Fig. 3a) . In agreement with results obtained for mouse Allergin-1, expressed on myeloid cell lineages, including monocytes, neutrophils and dendritic cells, from the peripheral blood also expressed human Allergin-1L and/or Allergin-1S1 (Fig. 3b) . Although T cells and natural killer cells did not express Allergin-1L or Allergin-1S1, we detected weak expression of Allergin-1L and/or Allergin-1S1 on B cells. We noted that unlike mouse Allergin-1, human Allergin-1L and/or Allergin-1S1 had considerable expression on peripheral blood basophils (Fig. 3b) . To determine whether Allergin-1 was expressed on human mast cells, we generated cultured mast cells derived from the CD34 + cells among the peripheral blood mononuclear cells. These cultured human mast cells also expressed Allergin-1L and/or Allergin-1S1 (Fig. 3c) , consistent with results obtained for mouse Allergin-1.
Mouse Allergin-1 recruits phosphatases
The cytoplasmic regions of human and mouse Allergin-1 contain six and five tyrosine residues, respectively. The tyrosine residues at positions 313 and 338 in humans and those at positions 216 and 241 in mice may form part of ITIM-like sequences (Figs. 1a and 4a) , which suggests that Allergin-1 may be tyrosine phosphorylated and could recruit phosphatases such as SHP-1 or SHP-2, or SHIP. To test that hypothesis, we treated mouse Allergin-1-expressing RBL-2H3 transfectants with pervanadate, which stimulates protein tyrosine phosphorylation. Immunoprecipitation of Allergin-1 with Flagspecific mAb demonstrated that Allergin-1 was tyrosine phosphorylated and recruited SHP-1, SHP-2 and SHIP (Fig. 4b) . To determine which tyrosine residues were phosphorylated and responsible for recruitment of the phosphatases, we established RBL-2H3 transfectants that stably expressed Flag-tagged mutant Allergin-1 in which the tyrosine residue at position 216 or 241, or those at both positions 216 and 241, were replaced with phenylalanine ( Supplementary Fig. 2 ). All the mutant Allergin-1 proteins, as well as wild-type Allergin-1, were tyrosine phosphorylated (Fig. 4b) , which suggested that tyrosine residues at positions other than 216 and 241 were also phosphorylated. Allergin-1 with substitution at residues 216 and 241 did not recruit SHP-1 or SHP-2 ( Fig. 4b) , which indicated that the presence of tyrosine residues at these positions was required for the recruitment A r t i c l e s of SHP-1 and SHP-2. In contrast, SHIP was recruited by each of the mutant allergin-1 proteins (Fig. 4b) , which suggested that the tyrosine residues at position(s) 175, 200 and/or 239 might be involved in the recruitment of SHIP.
Mouse Allergin-1 inhibits FcεRI-mediated degranulation Because mast cells have high surface expression of Allergin-1, we next examined whether mouse Allergin-1 mediates an inhibitory signal for the FcεRI-mediated degranulation of RBL-2H3 cells. We stimulated wild-type Allergin-1-expressing RBL-2H3 transfectants with IgE antibody to 2,4,6-trinitrophenyl (TNP) together with either TNPconjugated control antibody or Allergin-1-specific mAb. Coligation of Allergin-1 with FcεRI resulted in significantly less degranulation than did FcεRI stimulation alone, as determined by the release of β-hexosaminidase from the transfectants (Fig. 4c) ; this suggested that mouse Allergin-1 inhibits IgE-mediated degranulation of RBL-2H3 cells. However, degranulation was not affected in RBL-2H3 transfectants expressing mutant Allergin-1 with replacement of tyrosine at position(s) 216 and/or 241 with phenylalanine. This finding indicates that both tyrosine residues at positions 216 and 241 were involved in the inhibitory effect on degranulation. Together these results suggest that mouse Allergin-1 recruits SHP-1 and SHP-2 through the phosphorylation of tyrosine residues at positions 216 and 241 and mediates an inhibitory signal for FcεRI-mediated degranulation of RBL-2H3 cells.
Generation of Allergin-1-deficient mice
To study the function of Allergin-1 in immune responses, we generated mice lacking the gene encoding Allergin-1 (Allergin-1; A r t i c l e s Supplementary Fig. 3 ). Naive Allergin-1 −/− mice had normal composition of lymphocyte and myeloid cell populations in the spleen, bone marrow, thymus and peritoneal cavity (Fig. 5a,  Supplementary Fig. 4 and Supplementary Table 1) . Moreover, we did not observe any difference between wild-type and Allergin-1 −/− mice in the development of mast cells cultured from bone marrow cells in the presence of the cytokines interleukin 3 and stem cell factor (Fig. 5b) . These results suggest that disruption of Allergin-1 did not affect differentiation of hematopoietic cells, including mast cells.
To determine whether Allergin-1 inhibits FcεRI-mediated degranulation of mast cells, as well as of RBL-2H3 cells, we generated BMMCs from wild-type and Allergin-1 −/− mice (Fig. 5c) and stimulated the cells with IgE anti-TNP together with either TNP-conjugated control antibody or mAb to Allergin-1. Stimulation with mAb to Allergin-1 resulted in significantly less FcεRI-mediated release of β-hexosaminidase from wild-type BMMCs (P = 0.0008) but not from Allergin-1 −/− BMMCs (P = 0.074; Fig. 5d ). These results indicate that Allergin-1 inhibits FcεRI-mediated degranulation of BMMCs as well as RBL-2H3 cells.
Mouse Allergin-1 suppresses passive systemic anaphylaxis As Allergin-1 inhibited FcεRI-mediated degranulation of mast cells in vitro, we next determined whether Allergin-1 was involved in passive systemic anaphylaxis, an IgE-mediated type I immediate hypersensitivity reaction. We passively sensitized wild-type and Allergin-1 −/− mice with IgE mAb to TNP and then injected them intravenously with ovalbumin (OVA) or TNP-conjugated OVA (TNP-OVA). We measured rectal temperature, an indicator of passive systemic anaphylaxis, every 6 min after injection. Neither wild-type nor Allergin-1 −/− mice injected with OVA showed any change in rectal temperature. In contrast, wild-type mice challenged with TNP-OVA showed a progressive decrease in rectal temperature to 4 °C below the basal temperature by 18 min after injection, followed by a gradual recovery to basal temperature (Fig. 6a) . Allergin-1 −/− mice challenged with TNP-OVA showed significantly lower rectal temperatures than the corresponding Allergin-1 +/+ mice during the entire 180-minute observation period (Fig. 6a) .
Moreover, although mast cell-deficient (W sh /W sh ) mice did not show the decrease in rectal temperature, mice transplanted with BMMCs derived from Allergin-1 −/− mice showed significantly more passive systemic anaphylaxis than did those given transplantation of BMMCs derived from Allergin-1 +/+ mice (Fig. 6b) . These results suggest that Allergin-1 negatively regulates IgE-mediated mast cell activation in vivo and suppresses the type I immediate hypersensitivity reaction.
Mouse Allergin-1 suppresses passive cutaneous anaphylaxis We next determined whether Allergin-1 was also involved in IgE-mediated passive cutaneous anaphylaxis reaction in the ear, which typically develops in the late phase (2-6 h) after allergen exposure. We passively sensitized wild-type and Allergin-1 −/− mice by intravenous injection of dinitrophenol-specific IgE mAb and then challenged them by epicutaneous application of acetone and olive oil alone in the right ear and dinitrofluorobenzene (DNFB) in acetone and olive oil in the left ear. The net swelling in the left ear, as determined by the difference in the thickness of the left and right ears, of both Allergin-1 +/+ or Allergin-1 −/− mice was greatly increased by 4 h after the antigen challenge (Fig. 7a) . The ear swelling in Allergin-1 −/− mice was significantly greater than that in wild-type mice during the entire 50-hour observation period after the antigen challenge. In support of those results, histological analysis demonstrated that the ear swelling in Allergin-1 −/− mice 24 h after application of DNFB was considerably greater than that in wildtype mice (Fig. 7b) . 42 . In contrast, although PIR-B constitutively associates with SHP-1, it is dispensable for PIR-B-mediated inhibition of FcεRI-mediated mast cell activation 36 . An ITIM-recruiting molecule responsible for the suppression of mast cell activation by PIR-B has not yet been identified. We demonstrated that mouse Allergin-1 recruited SHP-1, SHP-2 and SHIP in RBL-2H3 cells stimulated with pervanadate. Allergin-1 with substitution of either Tyr216 or Tyr241 recruited neither SHP-1 nor SHP-2, which indicates that SHP-1 and SHP-2 require both tyrosine residues to bind to Allergin-1. Those results are in agreement with the functional analyses showing that the inhibitory effect of Allergin-1 on degranulation of mast cells required both Tyr216 and Tyr241. The KIR inhibitory natural killer cell receptors are also reported to require two ITIMs for the recruitment of tyrosine phosphatases and inhibitory signaling 43 . Allergin-1 with substitution at residues 216 and 241 was still tyrosine phosphorylated and recruited SHIP when stimulated with pervanadate, which suggests that tyrosine residues other than those at positions 216 and 241 (that is, position(s) 175, 200 and/or 239) are also phosphorylated and involved in the recruitment of SHIP. Nonetheless, our results suggest that SHP-1 and SHP-2, but not SHIP, are responsible for Allergin-1-based negative regulation of FcεRI-mediated degranulation of mast cells.
At present, a ligand for Allergin-1 has not yet been identified. However, Allergin-1-deficient mice showed enhanced IgEmediated, mast cell-dependent passive systemic anaphylaxis as early as 6 min after antigen challenge, which suggests that Allergin-1 on tissue mast cells might be tyrosine phosphorylated as a result of cis or trans interaction with a putative ligand expressed on mast cells themselves or surrounding cells in tissues before or just after antigen capture by FcεRI. PIR-B, which binds to major histocompatibility complex class I molecules 39 , is constitutively tyrosine phosphorylated 36 ; thus, it might be possible that PIR-B modulates basal activation of mast cells. However, FcγRIIB might downmodulate FcεRI-mediated signaling after binding to the IgG immune complex 44 . We observed neither tyrosine phosphorylation of Allergin-1 expressed on BMMCs or RBL-2H3 transfectants nor recruitment of phosphatases by Allergin-1 before stimulation of Allergin-1 with mAb in vitro. However, it remains undetermined whether Allergin-1 is constitutively tyrosine phosphorylated in vivo. To further understand the molecular mechanism of Allergin-1-mediated regulation of mast cell activation, it will be essential to identify a ligand for Allergin-1.
As Allergin-1 is expressed on mast cells but not on basophils in mice, the enhanced IgE-mediated allergic inflammation in Allergin-1-deficient mice was dependent on mast cells. However, we demonstrated that in humans, basophils as well as mast cells had abundant surface expression of Allergin-1. Studies have demonstrated that basophils are important in IgG-mediated systemic anaphylaxis and IgE-mediated chronic allergic inflammation in mice 11, 45, 46 . Although the role of basophils in human allergic inflammation remains undetermined, Allergin-1 might be involved not only in mast cell-dependent allergic responses but also in basophil-dependent allergic responses in humans.
We have demonstrated that Allergin-1 was expressed on macrophages, neutrophils and dendritic cells as well as mast cells and/or basophils in both humans and mice. Human Allergin-1 was also expressed on B cells. This broad expression pattern on various cell types is similar to that of other immunoglobulin-like inhibitory receptors, such as FcγRIIB, PIR-B, gp49B1, MAIR-I and SIRP-α. These receptors are involved in a variety of immune responses other than the activation of mast cells or basophils. For example, FcγRIIB interferes with B cell antigen receptor-mediated signals and inhibits B cell activation. Mice deficient in FcγRIIB are susceptible to induced autoimmune diseases, such as collagen-induced arthritis, and also spontaneously develop lupus in a strain-specific manner 14 . SIRP-α binds CD47, which is expressed on many cell populations, including red blood cells. Interaction with SIRP-α and CD47 constitutively inhibits FcγR-dependent and FcγR-independent phagocytosis by macrophages 47 . At present, the function of Allergin-1 in immune responses that involve myeloid cells other than mast cells remains to be defined. Further studies are needed to determine the role of Allegin-1 in allergic and nonallergic immune responses. 
